Probiotic mixture VSL#3:An overview of basic and clinical studies in chronic diseases

被引:1
|
作者
Fang-Shu Cheng [1 ,2 ]
Dan Pan [3 ]
Bing Chang [4 ]
Min Jiang [4 ]
Li-Xuan Sang [3 ]
机构
[1] Department of Dermatology,Shengjing Hospital of China Medical University
[2] China Medical University
[3] Department of Geriatrics,the First Affiliated Hospital,China Medical University
[4] Department of Gastroenterology,the First Affiliated Hospital,China Medical University
关键词
VSL#3; Intestinal barrier function; Chronic diseases; Intestinal microbial balance; Cytokines; Therapeutic use;
D O I
暂无
中图分类号
R96 [药理学];
学科分类号
100602 ; 100706 ;
摘要
Probiotics are known as "live microorganisms" and have been proven to have a health effect on hosts at the proper dose. Recently, a kind of probiotic mixture including eight live bacterial strains, VSL#3, has attracted considerable attention for its combined effect. VSL#3 is the only probiotic considered as a kind of medical food; it mainly participates in the regulation of the intestinal barrier function, including improving tight junction protein function, balancing intestinal microbial composition, regulating immune-related cytokine expression and so on. The objective of this review is to discuss the treatment action and mechanism for the administration of VSL#3 in chronic diseases of animals and humans (including children). We found that VSL#3 has a therapeutic or preventive effect in various systemic diseases per a large number of studies,including digestive systemic diseases (gastrointestinal diseases and hepatic diseases), obesity and diabetes, allergic diseases, nervous systemic diseases,atherosclerosis, bone diseases, and female reproductive systemic diseases.
引用
收藏
页码:1361 / 1384
页数:24
相关论文
共 50 条
  • [1] Probiotic mixture VSL#3: An overview of basic and clinical studies in chronic diseases
    Cheng, Fang-Shu
    Pan, Dan
    Chang, Bing
    Jiang, Min
    Sang, Li-Xuan
    WORLD JOURNAL OF CLINICAL CASES, 2020, 8 (08) : 1361 - 1384
  • [2] Probiotic mixture VSL#3: An overview of basic and clinical studies in chronic diseases (vol 8, pg 1361, 2020)
    Sang, Li-Xuan
    WORLD JOURNAL OF CLINICAL CASES, 2021, 9 (20) : 5752 - 5753
  • [3] Spotlight on VSL#3 probiotic mixture in chronic inflammatory bowel diseases
    Chapman, Therese M.
    Plosker, Greg L.
    Figgitt, David P.
    BIODRUGS, 2007, 21 (01) : 61 - 63
  • [4] Spotlight on VSL#3 Probiotic Mixture in Chronic Inflammatory Bowel Diseases
    Therese M. Chapman
    Greg L. Plosker
    David P. Figgitt
    BioDrugs, 2007, 21 : 61 - 63
  • [5] VSL#3 probiotic mixture - A review of its use in chronic inflammatory bowel diseases
    Chapman, Therese M.
    Plosker, Greg L.
    Figgitt, David P.
    DRUGS, 2006, 66 (10) : 1371 - 1387
  • [6] VSL#3: An analysis of basic and clinical contributions in probiotic therapeutics
    Gionchetti, P
    Lammers, KA
    Rizzello, F
    Campieri, M
    GASTROENTEROLOGY CLINICS OF NORTH AMERICA, 2005, 34 (03) : 499 - +
  • [7] Beneficial effects of a probiotic VSL#3 on parameters of liver dysfunction in chronic liver diseases
    Loguercio, C
    Federico, A
    Tuccillo, C
    Terracciano, F
    D'Auria, MV
    De Simone, C
    Blanco, CD
    JOURNAL OF CLINICAL GASTROENTEROLOGY, 2005, 39 (06) : 540 - 543
  • [8] VSL#3 Probiotic MixtureA Review of its Use in Chronic Inflammatory Bowel Diseases
    Therese M. Chapman
    Greg L. Plosker
    David P. Figgitt
    Drugs, 2006, 66 : 1371 - 1387
  • [9] Clinical experience with vsl#3 in patients with chronic pouchitis
    McLaughlin, S. D.
    Johnson, M. W.
    Clark, S. K.
    Tekkis, P. P.
    Ciclitira, P. J.
    Nicholls, R.
    GUT, 2008, 57 : A136 - A137
  • [10] Probiotic Therapy With VSL#3® in Patients With NAFLD: A Randomized Clinical Trial
    Derosa, Giuseppe
    Guasti, Luigina
    D'Angelo, Angela
    Martinotti, Chiara
    Valentino, Maria Chiara
    Di Matteo, Sergio
    Bruno, Giacomo M.
    Maresca, Andrea M.
    Gaudio, Giovanni V.
    Maffioli, Pamela
    FRONTIERS IN NUTRITION, 2022, 9